About
Inavya has developed AVATR, a regulated medical-grade device that connects to other medical devices – plus environmental, social and behavioural data – to enable people to live well when outside of the hospital. Inavya has a presence in the UK, Germany, Singapore, Brazil and Peru. Avatr is a CE marked medical device.
Key Facts
Avatr has contracts with some of the world’s leading hospitals to support service transformation in cardiac, cancer, and diabetes. These hospitals include InCor Hospital (cardiac) and The Cancer Institute (cancer) in Brazil.
Successes in UK/NHS
Leeds Teaching Hospitals: Following the successful initial patient trial we initiated in 2020, we are now launching a second larger trial demonstrating the effectiveness of Avatr in optimising the medical staff’s resources, in particular the nurses. For this trial we will receive a letter of intent from the head of the Cardiology Department, to confirm that he would consider procuring Avatr if it was proven to be successful in reducing nursing staff time. This study follows the same strategic approach we take with InCor in Brazil, where we gradually integrate the use of the Avatr within the medical teams and patients through phased studies, similar to a drug discovery process, ahead of a wide scale adoption. The ongoing engagement with Barts Hospital and Imperial College Healthcare are still making good progress and a number of new initiatives are currently being discussed. We will update you on the progress in our future newsletters.Company details
Solutions
Delivering advanced patient care
Enabling self-care
Specialism
Digitally-enabled out of hospital care
Specialised self-care (except mental health)
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.avatr.ai/Markets already exporting to
Brazil
Desired Markets
USA, Japan
Desired customer types
Hospitals, Pharma, Insurance, MedTech